Kugler J D, Danford D A
Department of Pediatrics, University of Nebraska Medical Center, Omaha68105.
Am Heart J. 1989 Mar;117(3):665-79. doi: 10.1016/0002-8703(89)90743-6.
This report reviews recent pacemaker technological advances as they apply to infants, children, and adolescents. Indications for pacemaker implantation in children have evolved since the 1984 Joint Task Force Guidelines. Recent data show that pacemaker implantation should be strongly considered in patients who have (1) asymptomatic congenital complete AV block with a mean heart rate less than 50 beats/min or other evidence of junctional instability; (2) congenital AV block with long QT interval; or (3) congenital long QT syndrome with bradyarrhythmias, or when conventional beta-blocker therapy is unsuccessful. Permanent pacemaker implantation is not necessarily an effective prophylactic measure against sudden death in patients following their operation who are receiving drug therapy for atrial tachyarrhythmias, and so is not absolutely indicated. New developments in lead technology have made transvenous lead systems more feasible for pediatric use. Because epicardial leads are required for small infants and for cosmetic reasons in some older children, design improvements are needed to enhance epicardial lead performance. Rate-responsive pacing is an acceptable alternative to dual-chamber pacing for augmenting exercise tolerance, and for children with sinus node dysfunction it is the preferred pacing mode. Pacemakers with automatic antitachycardia capabilities and with noninvasive electrophysiology features are valuable in children with atrial tachyarrhythmias. New data suggest that chronic atrial pacing also may be effective in controlling atrial tachyarrhythmias. New developments in pacemaker systems for the young parallel those for the older population, but differences between adult and pediatric patients demand ongoing increased participation by pediatric cardiologists.
本报告回顾了适用于婴儿、儿童和青少年的起搏器技术的最新进展。自1984年联合工作组指南发布以来,儿童起搏器植入的适应症已经有所发展。最近的数据表明,对于以下患者应强烈考虑植入起搏器:(1)无症状的先天性完全性房室传导阻滞,平均心率低于50次/分钟或有其他交界区不稳定的证据;(2)伴有长QT间期的先天性房室传导阻滞;或(3)伴有缓慢性心律失常的先天性长QT综合征,或常规β受体阻滞剂治疗无效时。对于接受房性快速心律失常药物治疗的术后患者,永久性起搏器植入不一定是预防猝死的有效措施,因此并非绝对必要。导线技术的新发展使经静脉导线系统在儿科应用中更可行。由于小婴儿需要心外膜导线,且一些大龄儿童出于美观原因也需要,因此需要改进设计以提高心外膜导线的性能。频率应答式起搏是增强运动耐量的双腔起搏的可接受替代方法,对于窦房结功能障碍的儿童,它是首选的起搏模式。具有自动抗心动过速功能和无创电生理特征的起搏器对房性快速心律失常的儿童很有价值。新数据表明,慢性心房起搏也可能有效控制房性快速心律失常。针对年轻人的起搏器系统的新发展与针对老年人群的类似,但成人和儿科患者之间的差异要求儿科心脏病专家持续增加参与度。